Open Accessibility Menu

Comprehensive Stroke Center

Highly-Specialized Stroke Care

A stroke is a medical crisis that demands urgency, ideally in the form of ambulance transportation to the emergency room. When a blood vessel is blocked or ruptures, lack of oxygen causes brain cells to die. Immediate, skilled care is vital.

Our stroke center is certified and designated an Advanced Comprehensive Stroke Center by The Joint Commission. Certification as a Comprehensive Stroke Center means that the organization has met The Joint Commission’s standards for Disease-Specific Care Comprehensive Stroke Center Certification, making it part of an elite group of providers focused on complex stroke care. Complex Stroke Centers are recognized as industry leaders and are responsible for setting the national agenda in highly-specialized stroke care. These centers have advanced infrastructure, staff, and training to receive and treat patients with the most complex strokes.

In addition, the center has been honored by the American Heart Association and the American Stroke Association with several awards, including the Gold Quality Award and Get with the Guidelines. We are especially proud of our Target Stroke Award, which recognizes our ability to provide rapid, emergent treatment. Our stroke center is the only recipient of this award in metropolitan Washington.

The hallmark of our stroke care is consistency. The emergency room neurologist follows patients for the duration of their hospital stays and after discharge.

Joint Commission seal with American Heart Association seal for comprehensive stroke center

Clinical Trials

  • INSYTE: Management of Parkinson’s Disease Psychosis in Actual Practice (The INSYTE Study)

    The INSYTE Study will examine the current disease progression of Parkinson’s disease Psychosis (PDP), the clinical, economic, and humanistic impact of anti-psychotic therapy in the management of the condition in real-world settings, and the burden of the condition on patients and their caregivers.

  • REFALS:EFFECTS OF ORAL LEVOSIMENDAN (ODM-109) ON RESPIRATORY FUNCTION IN PATIENTS WITH ALS

    This study will evaluate whether prolonged oral levosimendan can preserve respiratory function more effectively than placebo, resulting in better patient functionality as measured by the ALSFRS-R scale.

  • PENNANT: A Multicenter, Double Blind, Placebo Controlled Study to Assess the Efficacy and Safety of H.P. Acthar® Gel in the Treatment of Subjects With Amyotrophic Lateral Sclerosis

    The purpose of the PENNANT study is to evaluate the safety, tolerability, and effectiveness of the study drug (H.P. Acthar Gel®) in slowing the loss of motor skills or brain function in patients with ALS and to assess whether the study drug can increase an ALS patient’s life expectancy. Eligible participants will either receive the study drug or a placebo (inactive drug).

  • Protocol H8H-MC-LAIJ, Randomized Controlled Trial of Lasmiditan Over Four Migraine Attacks
    The objective of this Phase 3 study is to evaluate the efficacy of lasmiditan 200 mg and 100 mg on migraine headache pain freedom compared to placebo.
  • ARISE: pAdsevonil in drug-ResIStant Epilepsy: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PADSEVONIL AS ADJUNCTIVE TREATMENT OF FOCAL-ONSET SEIZURES IN ADULT SUBJECTS WITH DRUG-RESISTANT EPILEPSY, PHASE 2
    The primary objectives of this study are to characterize the dose-response relationship with respect to efficacy of PSL administered concomitantly with up to 3 anti-epileptic drugs (AEDs) for treatment of observable focal-onset seizures in subjects with drug-resistant epilepsy and to evaluate the efficacy of the 4 selected dose regimens of PSL compared with placebo. The secondary objective is to assess the safety and tolerability of all doses of PSL in relation to placebo.
  • A Randomized, Double-Blind, Placebo-Controlled, Phase 2 Study Exploring the Efficacy, Safety, and Tolerability of Natalizumab (BG00002) as Adjunctive Therapy in Adult Subjects With Drug-Resistant Focal Epilepsy
    The primary efficacy objective of the study is to determine if adjunctive therapy of natalizumab 300 mg intravenous (IV) infusion every 4 weeks reduces the frequency of seizures in adult subjects with drug-resistant focal epilepsy.
  • Low frequency electrical stimulation of the fornix in Intractable Mesial Temporal Lobe Epilepsy (MTLE)
    To develop a protocol to evaluate the safety and tolerability of low frequency stimulation of the fornix in patients with MTLE.